Occurrence, Impact, Analysis and Treatment of Metformin and Guanylurea in Coastal Aquatic Environments of Canada, USA and Europe

Adv Mar Biol. 2018:81:23-58. doi: 10.1016/bs.amb.2018.09.005. Epub 2018 Nov 7.

Abstract

This review discusses the occurrence, impact, analysis and treatment of metformin and guanylurea in coastal aquatic environments of Canada, USA and Europe. Metformin, a biguanide in chemical classification, is widely used as one of the most effective first-line oral drugs for type 2 diabetes. It is difficult to be metabolized by the human body and exists in both urine and faeces samples in these regions. Guanylurea is metformin's biotransformation product. Consequently, significant concentrations of metformin and guanylurea have been reported in wastewater treatment plants (WWTPs) and coastal aquatic environments. The maximum concentrations of metformin and guanylurea in surface water samples were as high as 59,000 and 4502ngL-1, respectively. Metformin can be absorbed in non-target organisms by plants and in Atlantic salmon (Salmo salar). Guanylurea has a confirmed mitotic activity in plant cells. Analysis methods of metformin are currently developed based on high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS). The removal of metformin from aquatic environments in the target regions is summarized. The review helps to fill a knowledge gap and provides insights for regulatory considerations. The potential options for managing these emerging pollutants are outlined too.

Keywords: Antidiabetic drug; Atlantic region; Coastal aquatic environments; Guanylurea; Metformin.

Publication types

  • Review

MeSH terms

  • Canada / epidemiology
  • Diabetes Mellitus / epidemiology
  • Europe / epidemiology
  • Humans
  • Metformin / chemistry*
  • United States / epidemiology
  • Urea / analogs & derivatives
  • Urea / chemistry*
  • Water Pollutants, Chemical / chemistry*

Substances

  • Water Pollutants, Chemical
  • Urea
  • Metformin